ERr 731® (Rheum rhaponticum extract)

Rheum rhaponticum
Evidence Level
Strong
3 Clinical Trials
5 Documented Benefits
4/5 Evidence Score

ERr 731® is a standardized extract of Siberian rhubarb (Rheum rhaponticum) root produced by Chemisches Laboratorium Dr. Kurt Richter and used as the active ingredient in branded menopause products such as Estrovera. It contains a defined profile of hydroxystilbene glycosides—rhaponticin, desoxyrhaponticin, and their aglycones rhapontigenin and desoxyrhapontigenin—that act as selective estrogen receptor beta agonists rather than ER-alpha activators. Several German-led randomized placebo-controlled trials in perimenopausal women have shown reductions in hot flushes and Menopause Rating Scale scores over 12 weeks, with open-label follow-up extending up to 96 weeks. It is positioned for women seeking non-hormonal options for vasomotor and mood symptoms during the menopausal transition.

Studied Dose One enteric-coated tablet daily standardized to 4 mg of the ERr 731 extract, taken consistently for at least 12 weeks; open-label extensions used the same daily dose up to 96 weeks.
Active Compound Hydroxystilbene glycosides rhaponticin and desoxyrhaponticin (with aglycones rhapontigenin and desoxyrhapontigenin); selective ER-beta agonists.

Benefits

Helps reduce menopausal hot flashes

Standardized rhubarb root extract has been shown in placebo-controlled trials in perimenopausal women to help lower the frequency and severity of hot flashes and night sweats as measured by the Menopause Rating Scale over twelve weeks of daily use.

Supports overall menopausal symptom relief

Daily use is associated with improvements in composite menopausal symptom scores covering vasomotor, psychological, and somatic complaints, supporting comfort during the perimenopausal transition without relying on hormone therapy.

Helps maintain mood and emotional balance

Trial data indicate improvements in subscales relating to anxiety, irritability, and depressed mood in perimenopausal women, helping support emotional well-being during a phase of fluctuating hormones.

Promotes better sleep quality during perimenopause

By reducing night sweats and overall climacteric symptom burden, the extract is associated with improvements in self-reported sleep quality and reductions in sleep disturbance scores in perimenopausal users.

Supports non-estrogenic hormonal balance

As a selective ER-beta-preferring botanical that does not measurably activate ER-alpha in standard assays, it offers menopausal symptom support without the endometrial proliferation associated with estrogenic stimulation of the uterus.

Mechanism of action

1

Selective ER-beta activation

The hyperestrolide aglycones rhapontigenin and desoxyrhapontigenin preferentially bind and transactivate estrogen receptor beta in cellular reporter assays while showing essentially no transactivation of ER-alpha, mimicking the receptor profile thought to mediate central menopausal symptom relief.

2

Modulation of hypothalamic thermoregulation

ER-beta activation in hypothalamic neurons is implicated in stabilizing the thermoregulatory set point, which is hypothesized to underlie the observed reductions in hot flash frequency and night sweats with ERr 731 supplementation.

3

Lack of uterotrophic ER-alpha signaling

Because the extract does not transactivate ER-alpha, preclinical and clinical safety data show no endometrial thickening or proliferation, distinguishing it from classical estrogen-containing menopause therapies.

4

Serotonergic and mood-related signaling

ER-beta signaling influences serotonergic neurotransmission relevant to mood and anxiety, providing a plausible mechanism for improvements in irritability, depressed mood, and anxiety subscales reported in trials.

Clinical trials

1
12-week RCT in perimenopausal women

Multicenter, randomized, double-blind, placebo-controlled trial; one enteric-coated ERr 731 tablet daily for 12 weeks.

109 perimenopausal women with climacteric complaints (Menopause Rating Scale II baseline).

ERr 731 produced significantly greater reductions in total MRS II score, in number and severity of hot flashes, and in individual symptom subscales compared with placebo. The extract was rated effective and well tolerated, with no estrogenic effects on the endometrium observed.

2
Confirmatory 12-week RCT

Multicenter, randomized, double-blind, placebo-controlled confirmatory trial; one ERr 731 tablet daily for 12 weeks.

112 perimenopausal women with menopausal symptoms.

Compared with placebo, ERr 731 significantly reduced the MRS total score and the number and severity of hot flashes, confirming efficacy for menopausal symptom management. The extract was well tolerated by the majority of women and no relevant safety signals were identified.

3
Long-term observational extension

Two consecutive 48-week prospective observational extensions following the initial RCT, totaling up to 96 weeks of ERr 731 exposure.

Perimenopausal women previously enrolled in the 12-week RCT who continued with open-label ERr 731.

Continued improvements in MRS II total and subscale scores were observed across the 96-week period, with sustained reductions in hot flashes and mood-related complaints and no adverse events linked to long-term use of the standardized rhubarb extract.

Side effects and drug interactions

Common Potential side effects

Mild gastrointestinal complaints such as stomach discomfort or nausea have been reported.
Occasional headache or dizziness was noted in clinical trial users.
Allergic-type skin reactions are uncommon but possible in sensitive individuals.
Breast tenderness has been reported infrequently during use.
No estrogenic endometrial thickening was observed but unscheduled bleeding warrants evaluation.

Important Drug interactions

May theoretically interact with hormone replacement therapy or oral contraceptives via ER signaling.
Caution is advised with tamoxifen or aromatase inhibitors due to estrogen receptor activity.
Concurrent use with other phytoestrogen supplements may compound estrogenic activity.
Theoretical interaction with anticoagulants such as warfarin warrants medical supervision.

Frequently asked questions about ERr 731® (Rheum rhaponticum extract)

What is the recommended dosage of ERr 731® (Rheum rhaponticum extract)?

The clinically studied dose for ERr 731® (Rheum rhaponticum extract) is One enteric-coated tablet daily standardized to 4 mg of the ERr 731 extract, taken consistently for at least 12 weeks; open-label extensions used the same daily dose up to 96 weeks.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is ERr 731® (Rheum rhaponticum extract) used for?

ERr 731® (Rheum rhaponticum extract) is studied for helps reduce menopausal hot flashes, supports overall menopausal symptom relief, helps maintain mood and emotional balance. Standardized rhubarb root extract has been shown in placebo-controlled trials in perimenopausal women to help lower the frequency and severity of hot flashes and night sweats as measured by the Menopause Rating Scale over twelve weeks of daily use.

Are there side effects from taking ERr 731® (Rheum rhaponticum extract)?

Reported potential side effects may include: Mild gastrointestinal complaints such as stomach discomfort or nausea have been reported. Occasional headache or dizziness was noted in clinical trial users. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does ERr 731® (Rheum rhaponticum extract) interact with medications?

Known drug interactions may include: May theoretically interact with hormone replacement therapy or oral contraceptives via ER signaling. Caution is advised with tamoxifen or aromatase inhibitors due to estrogen receptor activity. Consult a pharmacist or healthcare provider if you take prescription medications.

Is ERr 731® (Rheum rhaponticum extract) good for women's health?

Yes, ERr 731® (Rheum rhaponticum extract) is researched for Women's Health support. Standardized rhubarb root extract has been shown in placebo-controlled trials in perimenopausal women to help lower the frequency and severity of hot flashes and night sweats as measured by the Menopause Rating Scale over twelve weeks of daily use.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Heger M, Ventskovskiy BM, Borzenko I, Kneis KC, Rettenberger R, Kaszkin-Bettag M, Heger PW. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. Menopause. 2006;Menopause. 2006 Sep-Oct;13(5):744-59..PubMedUsed to support: Original 12-week RCT showing ERr 731 significantly reduced MRS II total score and hot flashes vs placebo in 109 perimenopausal women.
  2. Kaszkin-Bettag M, Ventskovskiy BM, Solskyy S, Beck S, Hasper I, Kravchenko A, Rettenberger R, Richardson A, Heger PW. Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms. Alternative Therapies in Health and Medicine. 2009;Altern Ther Health Med. 2009 Jan-Feb;15(1):24-34..PubMedUsed to support: Confirmatory 12-week RCT in 112 perimenopausal women showing significant MRS reductions and good tolerability vs placebo.
  3. Hasper I, Ventskovskiy BM, Rettenberger R, Heger PW, Riley DS, Kaszkin-Bettag M. Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum in perimenopausal women with menopausal symptoms. Menopause. 2009;Menopause. 2009 Jan-Feb;16(1):117-31..PubMedUsed to support: Two 48-week open-label extensions (up to 96 weeks) showing sustained MRS improvements and no long-term safety signals.
  4. Wober J, Möller F, Richter T, Unger C, Weigt C, Jandausch A, Zierau O, Rettenberger R, Kaszkin-Bettag M, Vollmer G. Activation of estrogen receptor-beta by a special extract of Rheum rhaponticum (ERr 731), its aglycones and structurally related compounds. Journal of Steroid Biochemistry and Molecular Biology. 2007;J Steroid Biochem Mol Biol. 2007;107(3-5):191-201..PubMedUsed to support: Mechanistic evidence that ERr 731 and its aglycones activate ER-beta but not ER-alpha in cellular reporter systems.